A First-in-Human Phase 1 Randomized, Singleascending Dose Study of VB421 (lonigutamab), an Anti-IGF-1R Monoclonal Antibody, in Healthy Volunteers

Monoclonal antibodies targeting insulin-like growth factor 1 receptor (IGF-1R) have been shown to be effective in the treatment of thyroid eye disease (TED). However, currently approved biologics are only available intravenously (IV). Additional therapies that support alternative routes of administration are needed, including therapies that can be subcutaneously (SC) administered. VB421 is a monoclonal antibody against IGF-1R that targets a unique epitope with picomolar affinity. The high affinity and resulting pharmacokinetic properties of VB421 may allow for SC administration in the treatment of TED.